62021TO0381_INF
Order of the General Court (Eighth Chamber) of 22 December 2021 –D & A Pharma v EMA
(Case T‑381/21)
(Action for annulment – Medicinal products for human use – Application for marketing authorisation for the medicinal product Hopveus – Non-renewal of a permanent scientific advisory group – No interest in bringing proceedings – Inadmissibility)
1.
Action for annulment – Natural or legal persons – Interest in bringing proceedings – Action capable of securing a benefit for the applicant – Action against a decision of the European Medicines Agency (EMA) not to renew a scientific advisory group – Interest relating to future and uncertain situations – No interest in bringing proceedings – Inadmissibility
(Art. 263, fourth para., TFEU)
(see paras 23-25, 27, 28, 35, 36, 41)
2.
Action for annulment – Jurisdiction of the EU judicature – Claim seeking that directions be issued to an institution – Not permissible
(Art. 263 TFEU)
(see paras 30, 31)
Re:
Application pursuant to Article 263 TFEU seeking annulment of the decision of EMA not to renew the scientific advisory group on psychiatry within the Committee for Human Medicinal Products, revealed implicitly by the public call for expression of interest for experts to become members of EMA’s scientific advisory groups and the press release of EMA of 5 May 2021.
Operative part
1.
The action is dismissed as being inadmissible.
2.
There is no longer any need to adjudicate on the application for leave to intervene submitted by the European Parliament.
3.
Debregeas et associés Pharma (D & A Pharma) shall pay the costs.
4.
The Parliament shall bear its own costs relating to its application for leave to intervene.